Advertisement
News
Advertisement

Aveo, Astellas to start renal cell carcinoma trial

Thu, 06/21/2012 - 9:37am
Mass High Tech: The Journal of New England Technology

Aveo Oncology (Nasdaq: AVEO) of Cambridge and Astellas Pharma Inc. (TSE: 4503) of Tokyo  said they plan to start a new clinical trial in advanced renal cell carcinoma to establish more data for their investigational drug tivozanib when used as a first-line therapy in those cancer patients.

The study is designed to build upon safety profile demonstrated in TIVO-1 study, according to a statement from the companies. In February 2011, Aveo and Astellas entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib to treat a broad range of cancers.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading